Skip to content

Efficacy of PRP for bone fusion in LLIF

Efficacy of platelet rich plasma for bone union on lateral lumbar interbody fusion surgery using unidirectional porous beta-tricalcium phosphate - LLIF-PRP

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTb032200199
Enrollment
15
Registered
2020-11-13
Start date
2021-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vertebral fracture, lumbar canal stenosis, lumbar spondylolisthesis, adult spine deformity

Interventions

A lumbar lateral interbody fusion is performed by the spinal cage with unidirectional beta-tricalcium phosphate (beta-TCP) artificial bone impregnating platelet-rich plasma (PRP) prepared from the pa

Sponsors

Yamazaki Masashi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who receives lateral lumbar interbody fusion surgery for vertebral fracture, lumbar canal stenosis, lumbar spondylolisthesis, adult spine deformity, and so on 2. Patients who receives lateral lumbar interbody fusion surgery at 1-4 levels 3. Patients over 20 years old 4. Patients with informed concent and understanding for treatment

Exclusion criteria

Exclusion criteria: 1. Patients with a history of lumbar surgery, purulent spondylitis, or spinal tumor 2. Patients who received other Investigational new drug within 3 months of participating in this clinical study 3. Patients who have a primary illness that is clearly inferior to bone formation (bone metabolic disease, dialysis, and so on) 4. Patients who have uncontrolled diabetes 5. Patients with anemia (Hb<9.0g/dL) 6. Patients who have disorder of blood coagulation. 7. Patients with rheumatoid arthritis who are using biologics with high risk of perioperative infection. 8. Women who are pregnant or suspected ofbeing pregnant or breastfeeding 9. Patients with metal allergy 10. Patients who needs the legal representative 11. Patients who are judged inappropriate by the responsible doctor for the study

Design outcomes

Primary

MeasureTime frame
Interbody fusion rate at postoperative 12 months

Secondary

MeasureTime frame
1. Interbody fusion rate at postoperative 6 months 2. bone remodeling and Absorption of artificial bone 3. Contact between the implanted beta- TCP and both upper and lower vertebral endplate 4. Clinical outcomes 5. back pain (Visual analog scale)

Countries

Japan

Contacts

Public ContactHiroshi Noguchi

University of Tsukuba Hospital

noguhiro0164@md.tsukuba.ac.jp+81-29-853-5625

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026